The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug ...

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

Sarepta Therapeutics said it will continue shipping its gene therapy Elevidys for Duchenne muscular dystrophy patients despite an FDA request to pause distribution following multiple patient deaths.

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

A disabled Oasis fan has described the 'biblical' scenes at Manchester's Heaton Park as other fans in the accessible area abandoned their crutches when the Gallagher brothers took to the stage.

Sarepta Therapeutics refused a FDA request to halt shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy ...

Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.